Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings historically submitted under the ticker NAOV for NanoVibronix, Inc., which subsequently changed its name to ENvue Medical, Inc. and its Nasdaq symbol to FEED. These documents provide a regulatory record of the company’s activities as a medical technology issuer focused on non-invasive therapeutic systems and minimally invasive navigation platforms.
Among the filings accessible here are Form 8-K current reports describing material events such as the corporate name change to ENvue Medical, Inc. and the symbol change from NAOV to FEED, the implementation of a 1-for-10 reverse stock split of common stock, and various financing transactions involving registered direct offerings, pre-funded warrants, and Series H Convertible Preferred Stock with associated warrants. Other 8-K filings discuss board and executive changes, special and annual meeting matters, and significant agreements.
The archive also includes a DEF 14A definitive proxy statement outlining proposals presented at the 2025 annual meeting of stockholders, including director elections, auditor ratification, amendments to equity incentive plans, and approvals required under Nasdaq Listing Rule 5635(d) for certain equity issuances. A Form 12b-25 (NT 10-Q) notification of late filing is available, explaining the need for additional time to complete a quarterly report for the period ended June 30, 2025.
On Stock Titan, these filings are presented with AI-powered tools that can help explain the structure and implications of documents such as 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements, and registration-related filings. Users can also review disclosures related to capital structure changes, preferred stock designations, warrant terms, and other corporate actions that shaped the company’s transition from NanoVibronix, Inc. (NAOV) to ENvue Medical, Inc. (FEED). For ongoing filings after the name and ticker change, investors should refer to submissions under the FEED symbol.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.
Bank of America Corp, Bank of America NA, and BofA Securities, Inc. jointly reported their initial beneficial ownership in Envue Medical, Inc. as 10% owners. The filing shows indirect ownership of 234,056 shares of common stock, held through Bank of America’s subsidiaries.
The 10% ownership status is based on 1,088,192 outstanding shares disclosed in Envue Medical’s Form 424B3 prospectus, which reports totals as of December 5, 2025. That prospectus covers the potential resale of up to 7,962,279 shares of common stock and notes that issuing additional shares could materially increase shares outstanding and substantially dilute existing stockholders.
ENvue Medical, Inc. entered into an Amendment Agreement with required holders of its Series H Convertible Preferred Stock. The parties agreed to amend the existing Certificate of Designations by filing a Certificate of Amendment that removes the defined Floor Price applicable to the Series H preferred.
In return, holders of the Preferred Stock agreed to exercise
ENvue Medical, Inc. filed an initial insider ownership report for director Pellegrino Pionati as of 12/04/2025. The filing states in the explanation that no securities are beneficially owned, meaning the director reported holding no shares or derivative securities of the company at that time. This is a routine disclosure required for company insiders when they first become subject to reporting rules.
ENvue Medical, Inc. filed an initial statement of beneficial ownership for a director, indicating that as of the event date of 12/04/2025 the reporting person did not beneficially own any company securities. The filing is made by a single reporting person in their capacity as a director and confirms there are no non-derivative or derivative securities reported as owned.